PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).

Abstract There is limited amount of data available on the comparative efficacy of ibrutinib and idelalisib, the B-cell receptor inhibitors (BCRi) newly approved for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL) treatment. The aim of our study was to analyze and compare the outcomes of real-world r/r CLL/SLL patients treated with these two BCRi in outside clinical trials.
PMID
Related Publications

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Authors

Mayor MeshTerms
Keywords

B-cell receptor inhibitors

Idelalisib

chronic lymphocytic leukemia

ibrutinib

rituximab

Journal Title anticancer research
Publication Year Start




PMID- 29715135
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20180508
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 5
DP  - 2018 May
TI  - Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in
      Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched
      Study of the Polish Adult Leukemia Group (PALG).
PG  - 3025-3030
AB  - BACKGROUND/AIM: There is limited amount of data available on the comparative
      efficacy of ibrutinib and idelalisib, the B-cell receptor inhibitors (BCRi) newly
      approved for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic
      lymphoma (r/r CLL/SLL) treatment. The aim of our study was to analyze and compare
      the outcomes of real-world r/r CLL/SLL patients treated with these two BCRi in
      outside clinical trials. PATIENTS AND METHODS: A comparative case matched 1:2
      analysis was performed on idelalisib combined with rituximab and ibrutinib
      efficacy in 102 patients with r/r CLL/SLL from two observational studies of the
      Polish Adult Leukemia Group (PALG). RESULTS: Both therapies produced similar
      overall response rates (idelalisib plus rituximab 76.4% and ibrutinib 72.1%).
      Median progression-free survival (PFS) and overall survival (OS) in both groups
      were not reached. Furthermore, no significant difference was observed between
      both BCRi regimens in regard to PFS (HR=0.75, 95% CI=0.30-1.86, p=0.55) and OS
      (HR=0.65, 95%CI=0.26-1.68, p=0.39). CONCLUSION: In summary, the results of this
      retrospective analysis suggest that idelalisib combined with rituximab and
      ibrutinib therapies have comparable activity in r/r CLL/SLL in daily clinical
      practice.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Pula, Bartosz
AU  - Pula B
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine,
      Warsaw, Poland [email protected]
FAU - Budziszewska, Bozena Katarzyna
AU  - Budziszewska BK
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine,
      Warsaw, Poland.
FAU - Rybka, Justyna
AU  - Rybka J
AD  - Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation,
      Wroclaw Medical University, Wroclaw, Poland.
FAU - Gil, Lidia
AU  - Gil L
AD  - Department of Hematology and Bone Marrow Transplantation, Karol Marcinkowski
      University of Medical Sciences, Poznan, Poland.
FAU - Subocz, Edyta
AU  - Subocz E
AD  - Department of Hematology, Military Institute of Medicine, Warsaw, Poland.
FAU - Dlugosz-Danecka, Monika
AU  - Dlugosz-Danecka M
AD  - Department of Hematology, Jagiellonian University, Krakow, Poland.
FAU - Zawirska, Daria
AU  - Zawirska D
AD  - Department of Hematology, Jagiellonian University, Krakow, Poland.
FAU - Waszczuk-Gajda, Anna
AU  - Waszczuk-Gajda A
AD  - Department of Hematology, Oncology and Internal Medicine, Medical University of
      Warsaw, Warsaw, Poland.
FAU - Iskierka-Jazdzewska, Elzbieta
AU  - Iskierka-Jazdzewska E
AD  - Department of Hematology, Medical University of Lodz, Copernicus Memorial
      Hospital, Lodz, Poland.
FAU - Kopacz, Agnieszka
AU  - Kopacz A
AD  - Department of Hematology, Specialist District Hospital, Rzeszow, Poland.
FAU - Szymczyk, Agnieszka
AU  - Szymczyk A
AD  - Department of Hematooncology and Bone Marrow Transplantation, Medical University 
      of Lublin, Lublin, Poland.
FAU - Czyz, Jaroslaw
AU  - Czyz J
AD  - Department of Hematology, Michal Kopernik University, Bydgoszcz, Poland.
FAU - Lech-Maranda, Ewa
AU  - Lech-Maranda E
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine,
      Warsaw, Poland.
AD  - Department of Hematology and Transfusion Medicine, Centre of Postgraduate Medical
      Education, Warsaw, Poland.
FAU - Warzocha, Krzysztof
AU  - Warzocha K
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine,
      Warsaw, Poland.
FAU - Jamroziak, Krzysztof
AU  - Jamroziak K
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine,
      Warsaw, Poland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (PCI 32765)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolinones)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - YG57I8T5M0 (idelalisib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Poland
MH  - Purines/therapeutic use
MH  - Pyrazoles/*therapeutic use
MH  - Pyrimidines/*therapeutic use
MH  - Quinazolinones/therapeutic use
MH  - Retrospective Studies
MH  - Rituximab/therapeutic use
OTO - NOTNLM
OT  - *B-cell receptor inhibitors
OT  - *Idelalisib
OT  - *chronic lymphocytic leukemia
OT  - *ibrutinib
OT  - *rituximab
EDAT- 2018/05/02 06:00
MHDA- 2018/05/09 06:00
CRDT- 2018/05/02 06:00
PHST- 2018/03/18 00:00 [received]
PHST- 2018/04/05 00:00 [revised]
PHST- 2018/04/10 00:00 [accepted]
PHST- 2018/05/02 06:00 [entrez]
PHST- 2018/05/02 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
AID - 38/5/3025 [pii]
AID - 10.21873/anticanres.12557 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557.